Biocorrx Inc. (OTCMKTS:BICX – Get Free Report) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,741 shares, an increase of ∞ from the June 30th total of 0 shares. Based on an average daily volume of 3,240 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.0% of the shares of the stock are sold short.
Biocorrx Stock Down 14.3%
OTCMKTS:BICX opened at $0.30 on Wednesday. The business’s 50-day moving average price is $0.35 and its 200 day moving average price is $0.35. Biocorrx has a 52-week low of $0.20 and a 52-week high of $1.28. The firm has a market cap of $8.90 million, a P/E ratio of -1.88 and a beta of 0.17.
Biocorrx (OTCMKTS:BICX – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.03. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.22 million.
About Biocorrx
BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.
See Also
- Five stocks we like better than Biocorrx
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
